• Je něco špatně v tomto záznamu ?

The anticancer activity of alpha-tomatine against mammary adenocarcinoma in mice

P. Tomsik, S. Micuda, L. Sucha, E. Cermakova, P. Suba, P. Zivny, Y. Mazurova, J. Knizek, M. Niang, M. Rezacova

. 2013 ; 157 (2) : 153-161.

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc14056221

AIM: To evaluate the anticancer effect of alpha-tomatine (i.p.) either alone or in combination with doxorubicin (i.v.) in a mouse tumour model. METHODS: We studied the effect of repeated alpha-tomatine (0.1 - 9 mg/kg) and/or doxorubicin (2 mg/kg) on the growth and mitotic activity of the solid Ehrlich tumour in vivo, as well as on the survival of the tumour-bearing mice. RESULTS: Monotherapy with alpha-tomatine had a significant dose-dependent anticancer effect which peaked at 1 mg/kg. This was shown by both slowed tumour growth and reduced tumour cell proliferation. We also provide the first evidence that the combination alpha-tomatine (1 mg/kg) and doxorubicin (2 mg/kg) had a synergistic effect and significantly prolonged the survival of the mice. Neither alpha-tomatine nor doxorubicin influenced the infiltration of tumours with CD3+ lymphocytes; nor were we able to find an in vivo modulation of the key molecules of two regulatory pathways reported in vitro as the principal anti-cancer mechanisms of alpha-tomatine, i.e. iNOS and phosphorylated ERK2. However, alpha-tomatine still led to intracellular DNA inhibition and protein synthesis in Ehrlich tumour cells in a short-term culture ex vivo with IC50 values of 8.7 and 6.6 µM. CONCLUSIONS: The results suggest that ΤΟΜ, especially in combination with doxorubicin, may be a promising agent for the treatment of malignant solid tumours. Despite growing knowledge of the mechanisms of ΤΟΜ action in cancer cells, most aspects remain unclear. Parallel organ toxicity, especially potential liver effects, requires careful attention when performing in vivo studies in the future.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14056221
003      
CZ-PrNML
005      
20210714142400.0
007      
ta
008      
140415s2013 xr ad f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2013.031 $2 doi
035    __
$a (PubMed)23681309
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Tomšík, Pavel, $d 1977- $7 xx0076495 $u Department of Medical Biochemistry, Charles University in Prague, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic
245    14
$a The anticancer activity of alpha-tomatine against mammary adenocarcinoma in mice / $c P. Tomsik, S. Micuda, L. Sucha, E. Cermakova, P. Suba, P. Zivny, Y. Mazurova, J. Knizek, M. Niang, M. Rezacova
520    9_
$a AIM: To evaluate the anticancer effect of alpha-tomatine (i.p.) either alone or in combination with doxorubicin (i.v.) in a mouse tumour model. METHODS: We studied the effect of repeated alpha-tomatine (0.1 - 9 mg/kg) and/or doxorubicin (2 mg/kg) on the growth and mitotic activity of the solid Ehrlich tumour in vivo, as well as on the survival of the tumour-bearing mice. RESULTS: Monotherapy with alpha-tomatine had a significant dose-dependent anticancer effect which peaked at 1 mg/kg. This was shown by both slowed tumour growth and reduced tumour cell proliferation. We also provide the first evidence that the combination alpha-tomatine (1 mg/kg) and doxorubicin (2 mg/kg) had a synergistic effect and significantly prolonged the survival of the mice. Neither alpha-tomatine nor doxorubicin influenced the infiltration of tumours with CD3+ lymphocytes; nor were we able to find an in vivo modulation of the key molecules of two regulatory pathways reported in vitro as the principal anti-cancer mechanisms of alpha-tomatine, i.e. iNOS and phosphorylated ERK2. However, alpha-tomatine still led to intracellular DNA inhibition and protein synthesis in Ehrlich tumour cells in a short-term culture ex vivo with IC50 values of 8.7 and 6.6 µM. CONCLUSIONS: The results suggest that ΤΟΜ, especially in combination with doxorubicin, may be a promising agent for the treatment of malignant solid tumours. Despite growing knowledge of the mechanisms of ΤΟΜ action in cancer cells, most aspects remain unclear. Parallel organ toxicity, especially potential liver effects, requires careful attention when performing in vivo studies in the future.
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorová antibiotika $x aplikace a dávkování $7 D000903
650    _2
$a bilirubin $x krev $7 D001663
650    _2
$a biologické markery $x metabolismus $7 D015415
650    _2
$a western blotting $7 D015153
650    _2
$a Ehrlichův tumor $x farmakoterapie $x metabolismus $7 D002286
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a doxorubicin $x aplikace a dávkování $7 D004317
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a játra $x účinky léků $7 D008099
650    _2
$a experimentální nádory mléčných žláz $x farmakoterapie $x metabolismus $7 D008325
650    _2
$a myši $7 D051379
650    _2
$a tomatin $x aplikace a dávkování $x analogy a deriváty $x farmakologie $7 D014053
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Mičuda, Stanislav, $d 1972- $7 jn20010309083 $u Department of Pharmacology, Charles University in Prague, Faculty of Medicine in Hradec Kralove, Hradec Kralove
700    1_
$a Suchá, Lenka $7 _AN074461 $u Department of Medical Biochemistry, Charles University in Prague, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Čermáková, Eva, $d 1952- $7 mzk2007401286 $u Computer Technology Centre, Charles University in Prague, Faculty of Medicine in Hradec Kralove, Hradec Kralove
700    1_
$a Šuba, Petr, $d 1949- $7 xx0076493 $u Department of Medical Biochemistry, Charles University in Prague, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Živný, Pavel, $d 1961- $7 mzk2006324255 $u Institute for Clinical Biochemistry and Diagnostics, University Hospital in Hradec Kralove, Hradec Kralove
700    1_
$a Mazurová, Yvona, $d 1951- $7 xx0054511 $u Department of Histology and Embryology, Charles University in Prague, Faculty of Medicine in Hradec Kralove, Hradec Kralove
700    1_
$a Knížek, Jiří $7 xx0105843 $u Department of Medical Biophysics, Charles University in Prague, Faculty of Medicine in Hradec Kralove, Hradec Kralove
700    1_
$a Niang, Mohamed, $d 1955-2016 $7 xx0076298 $u Department of Medical Biochemistry, Charles University in Prague, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Řezáčová, Martina, $d 1972- $7 nlk20020124956 $u Department of Medical Biochemistry, Charles University in Prague, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czech Republic $x 1213-8118 $g Roč. 157, č. 2 (2013), s. 153-161
910    __
$a ABA008 $b A 1502 $c 958 $y 4 $z 0
990    __
$a 20140415 $b ABA008
991    __
$a 20210714142358 $b ABA008
999    __
$a ok $b bmc $g 1025401 $s 854815
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 157 $c 2 $d 153-161 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK118 $a Pubmed-20140415

Najít záznam

Citační ukazatele

Možnosti archivace